Do you utilize Oncotype Dx or other multigene assays to guide adjuvant chemotherapy for ER+ HER2- breast cancers that are pT3N0?
Most guidelines recommended adjuvant chemotherapy if tumor size was >3cm at the time of TAILOR Rx and patients with tumors >5cm were not included in the trial's protocol. What factors influence your decision making?
Community PollStarted
Do you utilize Oncotype Dx or other multigene assays to guide adjuvant chemotherapy for ER+ HER2- breast cancers that are pT3N0?
129 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center
Answered on
Size matters when it comes to prognosis, but biology matters more when it comes to prediction of chemotherapy benefit. Evidence for the prospective Plan B trial indicating good prognosis in patients with high risk node-negative and 1-3 node-positive ER+, HER2- breast cancer with endocrine therapy al...
Join for free or sign in to see the full answer